Revolution in Anti-Obesity Drugs
80 years of tradition and innovation
This year, the pharmaceutical company Galenika celebrates 80 years of existence – a jubilee that provides an opportunity to look back on the company’s rich history and contribution to the pharmaceutical industry in Serbia and the region. Over the course of eight decades, Galenika has become synonymous with quality, reliability and innovation, building a reputation as a domestic pharmaceutical force that can be compared to leading European and global drug manufacturers.
Our mission throughout all these years has been the same – to improve the health and quality of life of patients, with a constant commitment to science and innovation,” points out Ricardo Vian Marques, CEO of Galenika.
From the first domestic medicines, through decades of intensive research and development, Galenika introduced numerous innovations that set standards in production and quality. The tradition, experience and expertise of the employees created the basis for new products that respond to the increasingly demanding needs of patients and the market. These eight decades of continuous commitment to quality and innovation represent the foundation on which Galenika is building its future today.
Peptides – an innovation in the treatment of obesity
And while Galenika’s history illuminates its successes, the company’s focus now and in the future is on innovations that change the standard of treatment. One of the key steps in this strategy is the development of a peptide platform and preparation for the launch of new drugs for the treatment of obesity. Medicines for the treatment of obesity based on peptides enable a targeted action on metabolic processes in the body, improving the effectiveness of the therapy, while at the same time reducing the side effects that are characteristic of traditional approaches.
Our vision is to be a leader in innovative obesity therapies, providing therapeutic solutions that truly make a difference in people’s lives,” says Ricardo Vian Marques.
Peptide-based drugs represent a global trend and one of the fastest growing segments of the pharmaceutical market. They enable personalized approaches and combination, opening up the possibility of more effective treatment. “Peptide-based obesity drugs are game-changers – they enable precise control over body weight and metabolic processes, which is key to the treatment of obesity and obesity-related diseases,” explains Marques.
Galenika is among the first producers of generic drugs in Serbia to launch such a platform, which enables the company not only to follow global trends, but also to set new standards. Galenika’s peptide platform is a great example of innovation as it represents a real revolution, both for the company here and for the pharmaceutical market as a whole.
Accelerated development of the pharmaceutical industry and the global context
Today, the pharmaceutical industry is going through accelerated changes – from the digitization of production and the development of biotechnology to the application of artificial intelligence and the growing awareness of health and disease prevention. Companies that do not innovate risk falling behind, while those that integrate new technologies and research can become global leaders.
Galenika is committed to meeting the challenges of the modern market by combining years of expertise and innovation to create products that change our patients’ lives for the better,” concludes Ricardo Vian Marques.
Obesity today represents a global health challenge with serious consequences for the quality of life and the health system. A new generation of drugs, including peptide therapies, enables more effective and targeted therapeutic treatments. Through a combination of tradition, scientific expertise and innovation, Galenika sets standards for the future of the pharmaceutical industry in Serbia and the region, confirming that innovation and quality can go hand in hand.
The text was published in the Special edition of the magazine ‘Biznis i Finansije’ and on the portal: Revolucija u lekovima protiv gojaznosti – Biznis i Finansije